SRR1473654
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.418
- INTERFERON_ALPHA_RESPONSE+0.371
- KRAS_SIGNALING_DN+0.365
- COAGULATION+0.245
- APICAL_SURFACE+0.197
- INTERFERON_GAMMA_RESPONSE+0.189
- MYOGENESIS+0.165
- BILE_ACID_METABOLISM+0.129
- ESTROGEN_RESPONSE_LATE+0.121
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.113
Top 10 suppressed
- MYC_TARGETS_V1-0.563
- MYC_TARGETS_V2-0.491
- UNFOLDED_PROTEIN_RESPONSE-0.476
- E2F_TARGETS-0.465
- PROTEIN_SECRETION-0.429
- G2M_CHECKPOINT-0.428
- DNA_REPAIR-0.414
- MTORC1_SIGNALING-0.368
- MITOTIC_SPINDLE-0.362
- UV_RESPONSE_DN-0.356
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1409534 | GTEX | — | 0.936 |
| 2 | SRR1315145 | GTEX | — | 0.925 |
| 3 | MDT-AP-1204 | Med | Medulloblastoma | 0.925 |
| 4 | SRR1455305 | GTEX | — | 0.919 |
| 5 | BS_0BXY0F9N | EPN | Posterior Fossa EPN | 0.909 |
| 6 | MNG1145 | — | — | 0.907 |
| 7 | SRR1310113 | GTEX | — | 0.906 |
| 8 | SRR1476186 | GTEX | — | 0.906 |
| 9 | SRR1479759 | GTEX | — | 0.905 |
| 10 | SRR1440962 | GTEX | — | 0.905 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.418 | Cobimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.371 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.365 | Remibrutinib | — uncovered |
| COAGULATION | 0.245 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.197 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.189 | Idelalisib | — uncovered |
| MYOGENESIS | 0.165 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.129 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.121 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.113 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.109 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.088 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.062 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.043 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.040 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.039 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.030 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.007 | Inavolisib | — uncovered |
| APOPTOSIS | 0.006 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.005 | Idelalisib | — uncovered |